This was chosen due to breast cancer being clearly delineated by receptor subtypes in a clinical setting; notably, the presence of the Estrogen Receptor (ER), Progesterone Receptor (PR) positive, human epidermal growth factor receptor 2 (HER2) positive. This evidence concerns the gene PGR and breast carcinoma.